Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 vs Vitamin K2: Omega-3 has the stronger overall evidence (9 vs 5/10); they're alternatives for prenatal support — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Helped
20 of 35 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Omega-3 and Vitamin K2 have evidence — compare verdict strength side-by-side.
A source-matched dose range is not available for this product and use.
With meals containing fat
Triglyceride form fish oil
A source-matched dose range is not available for this product and use.
With a meal containing fat
MK-7 (menaquinone-7)
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
4-12 weeks
1-3 years
1-3 years
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · RCT · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta-Analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta-Analysis · n=587
12 RCTs with 587 subjects: omega-3 supplementation increased serum BDNF versus placebo (SMD 0.72, 95% CI 0.28 to 1.15), with high heterogeneity (I2 = 84.39%).
Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial
Nutrients (2025) · RCT · n=151
The median age was 46 years; 71% were female and 29% were non-white.
The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis
Frontiers in endocrinology (2025) · Meta-Analysis · n=2570
Vitamin K2 (VK2) increased osteocalcin (OC; MD 1.86, 95% CI 1.17-2.56) and bone-specific alkaline phosphatase (BAP; MD 1.49, 95% CI 0.98-2.00).
Vitamin K2 in Managing Nocturnal Leg Cramps: A Randomized Clinical Trial
JAMA internal medicine (2024) · RCT · n=199
Of the 199 enrolled individuals, 108 (54.3%) were female, and the mean (SD) age was 72.3 (5.5) years.
Each estimate is a difference against placebo. Meta-analysis of 10 randomised trials, 1,426 adults, by EPA dose band. The bands were not randomised against each other. Source: PMID 37028202.
In a meta-analysis of 10 trials with 1,426 adults, the EPA dose band from 1 to under 2 g/day had an SMD of −0.43 (95% CI −0.79 to −0.07) for depression severity. The band at 2 g/day or more had an SMD of −0.20 (95% CI −0.48 to 0.07), so a benefit was not statistically demonstrated in that subgroup (PMID 37028202). Its estimate is −0.20, not zero. These are grams of EPA, not EPA plus DHA. The subgroup comparison does not show that 2 g/day is an exact threshold or that higher doses are less effective. The Cochrane review rated the overall depression evidence very low certainty and judged the small-to-modest effect unlikely to be clinically meaningful, with no demonstrated remission or response difference (PMID 34817851).
No dose-response chart is shown because we have not yet verified enough comparable dose-specific estimates and their uncertainty to support one.
In a 1-year randomised trial of 311 Chinese men and postmenopausal women, 90 μg of MK-7 a day slowed femoral neck bone loss in the postmenopausal women and 50 μg did not, with no effect in men (PMID 32060566). In a 3-year randomised placebo-controlled trial of 244 healthy postmenopausal women, 180 μg a day reduced the decline in bone density at the lumbar spine and femoral neck but not the total hip (PMID 23525894). In a 3-year randomised placebo-controlled trial of 142 postmenopausal women with osteopenia, 375 μg a day with calcium and vitamin D did not change bone density at any site (PMID 33030563). The curve stays flat above 90 μg because no trial compared 90 μg with a higher dose, and the 375 μg trial found no effect. The cited BMD meta-analyses do not state a dose and mostly pool menaquinone-4 trials, so they are not plotted.
Omega-3 has a higher evidence score (9/10 vs 5/10) and wins in 3 of 3 categories.
For prenatal support, Omega-3 has a higher relevance score (88 vs 20).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
Caffeine+L-theanine works; bacopa needs weeks; most "brain pills" are hype. The honest tier list.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.